Physician profile
Rebecca Roma
NPI 1366439747
$3,326,695.08
in general payments reported to CMS, 2019-2025
12 companies · $654K in 2025
The $654K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482K · 2020: $179K · 2021: $447K · 2022: $543K · 2023: $536K · 2024: $485K · 2025: $654K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.3M · Travel and Lodging: $205K · Consulting Fee: $120K · Food and Beverage: $35K · Honoraria: $4,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,310,656.89 |
| Travel and Lodging | $204,641.90 |
| Consulting Fee | $120,265.25 |
| Food and Beverage | $34,698.74 |
| Honoraria | $4,657.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $961,273.54 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $737,179.79 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $574,358.95 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $515,528.16 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $279,470.06 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $111,939.02 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105,137.38 | 2020-2025 | Caplyta |
| H. Lundbeck A S | $30,201.36 | 2019 | |
| Lundbeck LLC | $10,606.78 | 2020-2025 | Abilify Maintena |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $734.81 | 2019-2025 | Abilify Asimtufii |
| Allergan, INC. | $244.23 | 2019 | |
| Abbvie INC. | $21.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Roma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.